The gut hormone glucagon-like peptide-1 (GLP-1) and its analogues, which have been in clinical use for diabetes for over a decade, have useful appetite-suppressive effects and are now licensed for obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.